Custom Dulaglutide CAS NO:923950-08-7 Manufacturers, Service

Product Description

Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) analog with a potency approximately 30–150 times that of natural GnRH. As a GnRH agonist, it initially and briefly stimulates the pituitary gland to release gonadotropins (the "flare-up" effect). Subsequently, through sustained agonistic action, it leads to pituitary desensitization and downregulation of GnRH receptors, thereby inhibiting the secretion of gonadotropins (LH, FSH) and ultimately suppressing the production of sex steroid hormones.

Mechanism & Efficacy

Dulaglutide is a long‑acting glucagon‑like peptide‑1 (GLP‑1) receptor agonist. It mimics the action of endogenous GLP‑1, stimulating glucose‑dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety. These effects collectively contribute to improved glycemic control, reduced postprandial glucose levels, and weight management support in research models.

Dosage & Research Use

For research purposes, dulaglutide dosing is typically based on model specification (in vitro or in vivo) and experimental design. In preclinical rodent studies, doses often range from 0.1 mg/kg to 1 mg/kg administered subcutaneously once weekly. For larger animal models, dose adjustments are made according to body weight and pharmacodynamic response. Dulaglutide’s extended half‑life supports once‑weekly dosing in both preclinical and translational studies. Researchers should follow institutional guidelines and safety protocols when handling and dosing.

Patent & Intellectual Property

Dulaglutide is protected by multiple granted patents covering composition, formulation, and therapeutic use. Key patents include:

US8,940,878 B2 – GLP‑1 analogs and use for diabetes management (expected expiration 2029)
US10,531,146 B2 – Pharmaceutical composition and sustained‑release formulations (expected expiration 2031)
EP2263457 B1 – European patent covering dulaglutide compositions

These patents provide broad protection for GLP‑1 based peptide therapeutics, including dulaglutide analog structures, method of use claims for glycemic control, and related formulation technology in major markets.

Quality & Compliance

Dulaglutide supplied by ThinHeal is manufactured in a cGMP‑compliant facility, with rigorous quality control at each production stage. Each batch undergoes comprehensive testing for identity, purity, potency, and stability in accordance with international standards. Quality documentation, including Certificate of Analysis (CoA), is provided upon request to support regulatory or scientific use.

Customer Service & Shipping

ThinHeal is committed to providing dependable service and seamless logistics throughout the product lifecycle. Before shipment, all products are quality‑verified and labeled with batch information. We offer comprehensive shipping solutions, including cold‑chain packaging tailored to destination and transit duration, with tracking support available. After delivery, our team is available to assist with storage conditions, technical questions, and follow‑up documentation to support research continuity.

Frequently Asked Questions (FAQ)

1. What is the main mechanism of action of Deslorelin?
Deslorelin is a synthetic GnRH agonist that initially induces a brief "flare-up" release of gonadotropins, followed by sustained pituitary receptor downregulation to suppress sex steroid hormone production.
2. How does Dulaglutide function in research models?
As a long-acting GLP-1 receptor agonist, Dulaglutide mimics endogenous GLP-1 to stimulate glucose-dependent insulin secretion, inhibit glucagon release, delay gastric emptying, and support weight management research.
3. What are the typical dosing ranges for Dulaglutide in preclinical studies?
In rodent preclinical models, doses typically range from 0.1 mg/kg to 1 mg/kg administered subcutaneously once weekly, taking advantage of its extended half-life.
4. What intellectual property protects Dulaglutide formulations?
Key granted patents include US8,940,878 B2, US10,531,146 B2, and EP2263457 B1, covering GLP-1 analogs, composition structures, and sustained-release technology.
5. What quality standards are maintained by ThinHeal?
All products are manufactured in cGMP-compliant facilities and undergo thorough batch testing for purity, identity, potency, and stability, accompanied by a Certificate of Analysis (CoA).
6. How are temperature-sensitive products shipped?
ThinHeal provides temperature-controlled cold-chain packaging customized for transit duration, complete with tracking information and technical storage support post-delivery.

Related Products